AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 265.6 USD | +0.05% |
|
-1.75% | -7.77% |
| Apr. 15 | TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept | MT |
| Apr. 15 | Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
265.5
USD
Average target price
304.5
USD
Spread / Average Target
+14.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.77% | 142B | |
| +28.10% | 676B | |
| +24.27% | 559B | |
| -7.84% | 356B | |
| +14.71% | 320B | |
| +4.88% | 286B | |
| +2.62% | 213B | |
| +0.15% | 207B | |
| -9.41% | 199B | |
| -3.31% | 116B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- US Judge Handling Dispute Over Amgen Deal for Horizon Considers September Evidentiary Hearing
